These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 37272189)

  • 1. Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients.
    Zeng Q; Zhong Y; Yu X
    Ren Fail; 2023 Dec; 45(1):2210230. PubMed ID: 37272189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
    Zhao L; Liu A; Xu G
    Ren Fail; 2021 Dec; 43(1):1378-1393. PubMed ID: 34602015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Ferric Citrate on Hyperphosphatemia among Chinese Patients with Chronic Kidney Disease Undergoing Hemodialysis: A Phase III Multicenter Randomized Open-Label Active-Drug-Controlled Study.
    Wang Y; Chen X; Zhu H; Guo Z; Yang Y; Luo P; He Y; Xu Y; Ji D; Gao X; Sun X; Xing C; Wang Y; Wang X; Zhao S; Guan Y; Lin H; Zhong A; Shui H; Shao F; Lv L; Yan Y; Sun X; Zhang L
    Am J Nephrol; 2023; 54(11-12):479-488. PubMed ID: 37812931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
    Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
    Ruggiero B; Trillini M; Tartaglione L; Rotondi S; Perticucci E; Tripepi R; Aparicio C; Lecchi V; Perna A; Peraro F; Villa D; Ferrari S; Cannata A; Mazzaferro S; Mallamaci F; Zoccali C; Bellasi A; Cozzolino M; Remuzzi G; Ruggenenti P; Kohan DE;
    Am J Kidney Dis; 2019 Sep; 74(3):338-350. PubMed ID: 31027883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
    Rastogi A
    Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
    Floege J
    J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD.
    Lioufas NM; Pascoe EM; Hawley CM; Elder GJ; Badve SV; Block GA; Johnson DW; Toussaint ND
    J Am Soc Nephrol; 2022 Jan; 33(1):59-76. PubMed ID: 34645696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
    Palmer SC; Gardner S; Tonelli M; Mavridis D; Johnson DW; Craig JC; French R; Ruospo M; Strippoli GF
    Am J Kidney Dis; 2016 Nov; 68(5):691-702. PubMed ID: 27461851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.
    Navaneethan SD; Palmer SC; Vecchio M; Craig JC; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006023. PubMed ID: 21328279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.